A clinical study monitoring low-intensity anticoagulant therapy with a standard-sensitivity thromboplastin.
The ability of the prothrombin time to measure the anticoagulant effect of warfarin sodium varies depending on the particular tissue thromboplastin used in performing the test. Based on studies using sensitive thromboplastins, lower therapeutic ranges of anticoagulation are recommended. The adequacy of monitoring therapy in this lower range with the relatively insensitive thromboplastins commonly used in North America is unestablished. This 16-month prospective study used a standard North American thromboplastin to monitor 157 anticoagulated patients treated in a low therapeutic range. Of the 1734 prothrombin times generated, 876 (56%) were therapeutic, with 400 (23%) below and 458 (26%) above the therapeutic range. These results are comparable with those published in trials in which more sensitive thromboplastins were used in a similar therapeutic range. We conclude that standard North American thromboplastins are adequately suited to monitor therapy in this lower range.
Department of Medicine, Boston Veterans Affairs Medical Center, MA 02130.
M T
MT
Brophy
L D
LD
Fiore
J
J
Lau
E
E
Headley
M
M
Allen
D
D
Deykin
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011446:Prospective Studies; D011517:Prothrombin Time; D012015:Reference Standards; D012044:Regression Analysis; D012680:Sensitivity and Specificity; D013925:Thromboplastin / Q000737:chemistry
D000925:Anticoagulants; D013925:Thromboplastin